Integrating PSMA PET into Clinical Practice in Advanced Prostate Cancer

In the final episode of this commentary, ‘Integrating PSMA PET into Clinical Practice in Advanced Prostate Cancer,’ Dr. Neal Shore focuses on the practical integration of PSMA PET imaging into routine clinical care for patients with advanced prostate cancer. He emphasizes that the use of PSMA PET is no longer a question of “if,” but rather “when,” particularly for patients who have progressed following local therapies such as surgery or radiation. Across both biochemical recurrence and high-risk localized disease, PSMA PET is increasingly recognized as the most accurate imaging modality for staging and guiding treatment decisions. However, successful integration requires more than access to imaging; it depends on high-quality interpretation and actionable reporting. Ensuring that scans are read by experienced specialists and that reports are both comprehensive and understandable is critical for translating imaging findings into treatment decisions.

Dr. Shore also emphasizes the importance of developing familiarity with PSMA PET interpretation, particularly as these findings may differ from those seen with conventional imaging and reveal previously unrecognized disease patterns. As imaging technologies continue to evolve, including hybrid modalities such as PET/CT and PET/MRI, ongoing education and multidisciplinary collaboration will be critical to ensure accurate interpretation and appropriate clinical use. Overall, this segment highlights PSMA PET as a transformative advancement in prostate cancer care, with thoughtful integration into clinical workflows essential for optimizing outcomes in patients with advanced disease.

Thank you for watching this commentary for the Diagnostic Imaging Peers and Perspectives series on diagnostic imaging in advanced prostate cancer. Please subscribe to our newsletter for information on upcoming video series.